Two new vaccines that can prevent the transmission of meningitis bacteria from person to person have been discovered by investigators at the University of Southampton.
The vaccines do this by reducing 'carriage' of the responsible bacteria in the nose and throats of the population.
Meningitis is a devastating condition and the Southampton team believe this discovery will change the way new vaccines are made in the future.
"This study is telling us that the vaccines also have an effect on carriage in the throat and explains why they can be so effective across the population."
The study, published in The Lancet, took place over 10 centres across the UK and tested the effectiveness of two meningitis vaccines - MenACWY-CRM and 4CMenB - on participants aged 18 to 24 years old.
Participants were either given two doses of a control vaccine, two doses of the 4CMenB vaccine or one dose of MenACWY-CRM and then a placebo.
MenACWY-CRM was shown to reduce carriage rates by 39 percent while the 4CMenB vaccine, which was recently approved by the Joint Committee on Vaccination and Immunisation (JCVI) in March, reduced carriage rates by between 20 and 30 percent.
Meningitis is an infection of the meninges - the membrane that surrounds the brain and spinal cord. Meningococcal bacteria are common and carried harmlessly in the nose or throat by about one in 10 people and are passed on through close contact. Anyone can get meningitis, but babies and young children are most vulnerable.
Professor Read adds: "This is a significant piece of work in helping more and more people be protected from meningitis. We have shown that vaccines modify the way the bacteria are carried, so even when the antibodies are no longer present in the blood, the carriage in the throat is still prevented, and so is onward transmission of the infection to others. This could provide a degree of herd protection against meningitis if implemented in a campaign in which high transmission occurs, for example in teenagers and young adults."